This paper aims to study the potential biological mechanism of Üstikuddus Sherbiti (ÜS) in the treatment of ischemic cerebrovascular diseases (ICVD) by the network pharmacology method. Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to obtain effective constituents of ÜS by screening eligible oral utilization, drug similarity, and blood-brain barrier permeability threshold. By drug target prediction and stroke treatment target mining, 2 target data sets were analyzed to find intersection targets and the corresponding constituents were used as active constituents. An active constituent target network and an effective constituent target network were constructed by using Cytoscape 3.7.2 software. Degree parameters of the effective constituent target network were analyzed to find important effective constituents and targets. Through protein-protein interaction (PPI) analysis/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, potential signaling pathways of ÜS in ischemic stroke were found out. AutoDock was used for molecular docking verification. A total of 90 active constituents of ÜS were screened out. There were 10 active constituents against ICVD, including quercetin, luteolin, kaempferol, and naringenin, and 10 important targets for anticerebral ischemia, namely, PIK3CA, APP, PIK3R1, MAPK1, MAPK3, AKT1, PRKCD, Fyn, RAC1, and NF-κB1. Based on the protein interaction network, the important targets of ÜS were significantly enriched in PI3K-Akt signaling pathway, neuroactive ligand-receptor interaction pathway, Ras signaling pathway, etc. ÜS in ICVD has characteristics like multiple targets, multiple approaches, and multiple pathways. Results of molecular docking showed that the active components in ICVD had a good binding ability with the key targets. Its main biological mechanism may be related to the PI3K-Akt and Ras-MAPK centered signaling pathway. Our study demonstrated that ÜS exerted the effect of treating ICVD by regulating multiple targets and multiple channels with multiple components through the method of network pharmacology and molecular docking.

Objective: To evaluate the clinical effect of Üstikuddus sherbiti (US), a traditional herbal prescription of Uyghur medicine, in the treatment of cold and dry-type major depression disorder (MDD) patients with comorbid anxiety. Methods: A total of 150 cold and dry-type depressive patients with comorbid anxiety were randomly divided into three groups of 50 patients; then they were, respectively, treated with US, modern medicine Fluoxetine, and the combination of Fluoxetine and US. The depression degrees of patients were evaluated zero and six weeks after the treatment based on the Hamilton Anxiety Scale (HAMA), in the clinical study. Analysis of variance (ANOVA) was used to detect significant differences at various time points or among the three groups. Statistical analysis was performed by SPSS version 21.0. Results: The main results are as follows: After taking the medicine, the depressive condition of patients with comorbid anxiety in the three groups was getting better with the passage of time; particularly, the clinical efficacy of US combined with Fluoxetine was significantly improved, indicating that the effect of combined treatment is better than treatment with pure Fluoxetine or pure US treatment. Statistical difference exists between the end time point within groups, but not among the three groups. Moreover, in the detection process of the patient’s physical indicators, no obvious side effects were found. These results together suggested that US can strengthen the curative effect of modern medicine in the treatment of depression, which would lay a foundation for studying the molecular mechanism and potential target of US. Conclusion: Fluoxetine and US combination therapy played a significant role in the treatment of depressive symptoms, suggesting that it can improve the curative effect of depression. The study provided a new way of thinking to clarify the US molecular mechanism for the treatment of depression and potential target.

Background: Ascariasis is one of the common intestinal infections in developing countries, including China. Migration of Ascaris lumbricoides into the gallbladder is rare, unlike ascariasis of the bile duct and when it does occur, treatment is generally by endoscopic or surgical extraction. Case presentation: A 4-year-old Uyghur boy with a history of ascariasis developed intermittent upper abdominal pain for 7 days, was being treated by a local practitioner, and when the pain worsened with yellow sclera for 3 days, he was admitted to our hospital. On physical examination, found out the patient with yellowish skin tone, pale yellow fur on tongue, mild yellow staining of the sclera and tenderness in epigastrium. Laboratory data plus liver function test showed damage of liver function. Abdominal Ultrasonography (USG) and Magnetic resonance cholangiopancreatography (MRCP) showed a long, linear, echogenic structure in the gallbladder neck near to the common bile duct. Once the ascariasis diagnosis was established, he was given conservative treatment of magnesium sulfate with herbal medicine. In 4 days, the patient discharged Ascaris through the stool. Conclusions: Conservative treatment of magnesium sulfate with Uyghur medicine treatment according to syndrome differentiation is proven to have curative effect.